🏢 官网IRIBMQwen · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 09-09(美东日)仅日期·⟳ 抓取 12:21:04回填·⚡ 决策 09-09 13:32:45·48.2 天前
IBM 与 Cleveland Clinic、RIKEN 联合团队入围 2026 年 ACM 戈登·贝尔奖决赛，完成 12,635 原子生物分子量子模拟，无订单或收入增量
事件是学术奖项『入围』而非获奖，稿件不含任何订单金额、收入、机时合同、客户付费或指引变化；对市值约 2,187 亿美元的 IBM 而言属无金额增量的软催化，且核心科研成果自述首发于 2026 年 5 月。跨市场映射侧亦无因果链：所用超算为日本国立系统，未点名任何上市供应商/客户，A 股『量子科技』概念成员仅有板块归属、无敞口证据。市场层面亦未见重定价——IBM 夜盘 +0.08%、成交仅 2,037 股。故无可交易边界，输出 AVOID，且不生成风险信号（无净负面事实）。
📄 原文IBM↗ 原文
Cleveland Clinic, RIKEN and IBM Team Advance to Finals for 2026 ACM Gordon Bell Prize
CLEVELAND, WAKO, JAPAN and YORKTOWN HEIGHTS, N.Y. — Sept 9, 2026 — A multidisciplinary team from Cleveland Clinic, RIKE…
不做 IBM（IBM.US）
学术奖项『入围』类软催化，稿件无任何订单、收入、机时合同或指引增量，且核心成果自述 2026 年 5 月已首发；对市值约 2,187 亿美元的超大市值主标的不构成短线可交易 edge（发布后夜盘仅 +0.08%、成交 2,037 股，无重定价）。二阶映射亦不成立：计算平台为 RIKEN Fugaku/Miyabi-G/ROQUO 等国立超算，未点名任何上市供应商或客户，A 股『量子科技』概念成员只有板块归属、无敞口证据，不做题材联想。空头方向同样不成立（无公司级净负面事实，…
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事实：IBM 官方 newsroom 一手稿（2026-09-09 04:20 UTC）宣布与 Cleveland Clinic、RIKEN 的团队入围 2026 年 ACM 戈登·贝尔奖决赛，成果为 12,635 原子生物分子量子模拟，获奖结果 2026-11 才公布；稿件明确说明研究成果 2026 年 5 月首发、9 月更新，资助方为日本 NEDO/METI，全文无金额、无订单、无商业条款。影响链：奖项入围→声誉与技术验证→无法穿透到 IBM 任一财务科目（收入/毛利/订单/capex/指引），也无法穿透到任何上市公司供应链（计算平台为 RIKEN Fugaku、Miyabi-G、ROQUO 等国立超算）。价格与证据：stock_quote 显示 IBM 现价 232.09 美元、市值 2,186.6 亿美元、20 日波动率 1.61%、近 13 周轨迹自 100 跌至 85（下行趋势）、距 60 日高 -25.0%；发布后夜盘仅 +0.08%、成交 2,037 股，盘后 -0.04%，无重定价迹象，也无抢跑放量。跨源查重 72 小时窗口 0 命中，说明这不是重复消息，但重复与否不改变其非交易性。结论：无金额增量的超大市值软催化 + 无可坐实的二阶映射标的 → AVOID；事件方向记为 POSITIVE（声誉层面正面），但不足以形成入场 edge。
🔎 新鲜度:最早出现 2026-09-09 · 扩散 low · price-in 风险 low ↗
关键理由
- 不建立多头理由：入围奖项目前只是学术声誉与技术验证，稿件未披露任何合同、机时销售或收入增量，无法在可交易窗口内改变 IBM 的收入/利润/capex/指引
- 不建立空头理由：无公司级净负面事实，反而对量子平台叙事偏正面，做空红线①②均不满足
- 二阶映射不成立：所用超算为日本国立系统（Fugaku/Miyabi-G/ROQUO），未点名任何上市供应商或客户，A 股量子概念成员仅有板块归属、无敞口证据
主要风险
- 若后续 SC26 公布获奖并同步披露量子业务付费客户/机时合同，则事件性质会从软催化升级为可交易催化，需重新研判（当前不构成交易）
- IBM 近 13 周指数化轨迹自 100 下行至 85、距 60 日高 -25%，属下行趋势背景；即便未来出现正面催化，追多的技术环境亦偏逆风
反向证据
- 做多前查反向 · 来源 filing · 日期 2026-09-09 · 影响 invalidates
以公司一手新闻稿全文为反证核查对象：稿件仅含技术成果、团队名单与 NEDO/METI 资助说明，未出现任何金额、客户付费、机时合同或指引调整表述；资助方为日本政府机构，不改变 IBM 收入
检索:IBM 量子计算 戈登·贝尔奖 入围 订单 收入 商业条款 / IBM quantum revenue contract 2026 原文 ↗ - 做多前查反向 · 来源 filing · 日期 2026-09-08 · 影响 weakens
stock_quote(full) 显示近 13 周指数化轨迹 100→85（中途低至 77）为下行形态，近 5 日 -0.76%、近 20 日 -1.79%，vol_spike_x=0.99 无异常放量，事件前 1-2 日无抢跑；同时下行趋势意味着即便有催化，追多的技术环境亦不利
检索:IBM 近期股价轨迹与是否已抢跑（path_13wk_idx100 / 近 20 日逐日 / 盘后量能）
先例如何影响了这次决策
对本次决策的影响:先例未改变标的、方向、仓位或订单参数；结论完全由『无金额增量 + 无可坐实映射标的 + 无市场重定价』三项当前事实决定
方向:不适用：本次不建立任何方向性仓位，先例的方向/胜率读数不会改变 AVOID 结论
涨幅量级:未用先例校准幅度。事件本身无金额增量（奖项入围、无订单/收入），即使取得同类『学术奖项入围』先例的涨幅分布，也无法为一个没有财务传导的催化定 tp/sl
形态:未观察到本次事件的高开低走/见光死迹象：一手稿发布后 IBM 夜盘仅 +0.08%、成交 2,037 股，盘后 -0.04%，属无反应而非派发
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 88 ms
{"result": "search_processed_events:agent query=`cleveland clinic riken ibm 量子 蛋白质模拟 finalist | ibm quantum gordon bell 2026 sc26 | ibm 量子计算 gordon bell prize 入围 | 量子-经典超算 药物发现 12635 原子 ibm heron`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 21.9/72 小时、1299 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不 - fetch_decision_experience 成功 stock_tools HTTP · 9 ms
{ - stock_quote 成功 stock_tools HTTP · 1,108 ms
{ - get_stock_profile 成功 stock_tools HTTP · 91 ms
{"result": "## 「量子科技」成分股\n\n**作为概念板块**（列出 20 只，上限 20）：\n中兴通讯(000063.SZ)、中国长城(000066.SZ)、长虹美菱(000521.SZ)、神州信息(000555.SZ)、华工科技(000988.SZ)、金房能源(001210.SZ)、东信和平(002017.SZ)、星光股份(002076.SZ)、恒宝股份(002104.SZ)、中航光电(002179.SZ)、天融信(002212.SZ)、科大讯飞(002230.SZ)、电科网安(002268.SZ)、光迅科技(002281.SZ)、科华数据(002335.SZ)、启明星辰(
原文全文
展开原文 · 8,450 字
CLEVELAND, WAKO, JAPAN and YORKTOWN HEIGHTS, N.Y. — Sept 9, 2026 —
A multidisciplinary team from Cleveland Clinic, RIKEN and IBM (NYSE:
IBM
) has been named as a finalist for the 2026 Association for Computing Machinery (ACM)
Gordon Bell Prize
for simulating the largest biologically meaningful molecules ever modeled with quantum computers, reaching a scale of 12,635 atoms. To achieve these results, the team united the strengths of quantum and classical computing methods in a framework known as quantum-centric supercomputing.
The ACM Gordon Bell Prize recognizes outstanding achievement in high-performance computing and is one of the field's most prestigious honors. The 2026 winner will be announced at the
International Conference for High-Performance Computing, Networking, Storage, and Analysis
(SC26), taking place Nov. 15–20, 2026 in Chicago.
The origins of the project are rooted in the team’s investigation into how computation in drug discovery can be improved. Doing so rests on two fundamental challenges: first, modeling the movement of atoms as biological processes unfold; and second, accurately computing their energies. Particularly the second challenge is well-suited for quantum computers, which operate by the laws of quantum mechanics.
In the work, initially published in May 2026, the team calculated the electronic structure of two large protein complexes using the IBM Quantum Heron processors running within the IBM quantum computers at Cleveland Clinic in the United States and RIKEN in Japan. The calculations were executed alongside two of the world’s most powerful supercomputers, Fugaku at RIKEN and Miyabi-G, which is operated by the University of Tokyo and University of Tsukuba. The quantum computers used up to 94 qubits to run nearly 6,000 quantum operations within certain parts of the problem, which was essential to the computation’s accuracy and success. Fugaku and Miyabi-G were used to reassemble the results and allow the team to gain a complete representation of each molecule.
The results reflect the team’s innovative approach alongside the rapid maturation of quantum computing. Using the sample-based quantum diagonalization by IBM and RIKEN (featured on the cover of
Science Advances)
along with embedded wavefunction methods adapted by Cleveland Clinic to the question at hand, the team was able to report the first-known simulation of a
303-atom protein
achieved with quantum computers. Less than a year later, the team first scaled their method roughly 40 times while also achieving 210 times improvement in accuracy. In updated results recently published in September, the team advanced the work even further. Most notably, they were able to further improve the accuracy of their computations of the binding energies of the molecular system, which reflect how tightly the molecules are bound together and can predict how they could interact with other systems.
In addition, the team validated the workflow on a third supercomputer, JHPC-quantum GPU supercomputer “
ROQUO
,” RIKEN's newest system in a way that eliminated the need for complex manual operations and data transfers – pointing toward faster, more accessible research. By orchestrating CPUs, GPUs, and QPUs together, the team minimized the need for manual transfers and further reduced errors — an early demonstration of how classical and quantum computing can work in concert on complex scientific problems.
Taken together with the earlier results, these updates reflect continued progress on both the accuracy of computed binding energies and the time-to-solution enabled by the automated workflow.
The quantum-classical techniques developed by the team continues to reduce the computational overhead required to directly represent the chemistry of molecular systems with accuracy and is pushing the frontiers of what is possible with quantum-centric supercomputing in the field. The work has demonstrated a path to further increase the accuracy of how molecular system can be calculated and is a step towards helping researchers better predict how medicines may interact with protein targets.
The research team includes Kenneth Merz Jr, Akhil Shajan, Danil Kaliakin, Fangchun Liang of Cleveland Clinic, Yuichi Otsuka, Tomonori Shirakawa, Lukas Broers, Han Xu, Miwako Tsuji, Mitsuhisa Sato, Seiji Yunoki of RIKEN Center for Computational Science, and Ryo Wakizaka, Yukio Kawashima, Jun Doi, Hitomi Takahashi, Toshinari Itoko, Hiroshi Horii, Thaddeus Pellegrini, Javier Robledo Moreno, Kevin J. Sung, Ella Fejer, Robert Walkup, Seetharami Seelam, Mario Motta of IBM.
To read the full study, visit:
https://arxiv.org/abs/2605.01138
.
Research Support
This research is supported by NEDO (New Energy and Industrial Technology Development Organization), an organization under the jurisdiction of Japan's Ministry of Economy, Trade and Industry (METI)'s "Research and Development of Quantum-Supercomputers Hybrid Platform for Exploration of Uncharted Computable Capabilities" (Project Leader: Mitsuhisa Sato) as part of the "Project for Research and Development of Enhanced Infrastructures for Post 5G Information and Communications Systems (JPNP20017)."
About Cleveland Clinic
Cleveland Clinic
is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation, Cleveland Clinic has pioneered many
medical breakthroughs
, including coronary artery bypass surgery and the first face transplant in the United States. Cleveland Clinic is consistently recognized in the U.S. and throughout the world for its expertise and care. Among Cleveland Clinic’s 83,000 employees worldwide are more than 6,600 salaried physicians and researchers, and 21,900 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,725-bed health system that includes a 173-acre main campus near downtown Cleveland, 23 hospitals, 300 outpatient facilities, including locations in northeast Ohio; Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2025, there were 15.9 million outpatient encounters, 343,000 hospital admissions and observations, and 336,000 surgeries and procedures throughout Cleveland Clinic’s health system. Visit us at
clevelandclinic.org
. Follow us at
x.com/CleClinicNews
. News and resources are available at
newsroom.clevelandclinic.org.
About RIKEN
RIKEN is Japan’s leading national comprehensive research institute in the natural sciences, conducting research across a broad range of fields including physics, engineering, chemistry, mathematical and information sciences, computational science, biology, and medical science. The RIKEN Center for Computational Science (R-CCS) operates the world-class supercomputer Fugaku, providing computing resources to a wide range of users in universities, research institutions, and industry, and carries out research and development under the banner of “The Science of computing, by computing, and for computing”, contributing to the advancement of computational science and computer science.
For more information, visit
https://www.riken.jp/en/
.
About IBM
IBM is a leading global hybrid cloud and AI, and business services provider, helping clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM's legendary commitment to trust, transparency, responsibility, inclusivity and service.
For more information, visit
https://research.ibm.com
.
Media contacts:
Alicia Reale-Cooney
Cleveland Clinic
realeca@ccf.org
(216) 408-7444
R-CCS, Computational Science Promotion Division Outreach Group
r-ccs-koho@ml.riken.jp
Danielle Cerasani Estevez
IBM Research Communications
dcerasani@ibm.com
A multidisciplinary team from Cleveland Clinic, RIKEN and IBM (NYSE:
IBM
) has been named as a finalist for the 2026 Association for Computing Machinery (ACM)
Gordon Bell Prize
for simulating the largest biologically meaningful molecules ever modeled with quantum computers, reaching a scale of 12,635 atoms. To achieve these results, the team united the strengths of quantum and classical computing methods in a framework known as quantum-centric supercomputing.
The ACM Gordon Bell Prize recognizes outstanding achievement in high-performance computing and is one of the field's most prestigious honors. The 2026 winner will be announced at the
International Conference for High-Performance Computing, Networking, Storage, and Analysis
(SC26), taking place Nov. 15–20, 2026 in Chicago.
The origins of the project are rooted in the team’s investigation into how computation in drug discovery can be improved. Doing so rests on two fundamental challenges: first, modeling the movement of atoms as biological processes unfold; and second, accurately computing their energies. Particularly the second challenge is well-suited for quantum computers, which operate by the laws of quantum mechanics.
In the work, initially published in May 2026, the team calculated the electronic structure of two large protein complexes using the IBM Quantum Heron processors running within the IBM quantum computers at Cleveland Clinic in the United States and RIKEN in Japan. The calculations were executed alongside two of the world’s most powerful supercomputers, Fugaku at RIKEN and Miyabi-G, which is operated by the University of Tokyo and University of Tsukuba. The quantum computers used up to 94 qubits to run nearly 6,000 quantum operations within certain parts of the problem, which was essential to the computation’s accuracy and success. Fugaku and Miyabi-G were used to reassemble the results and allow the team to gain a complete representation of each molecule.
The results reflect the team’s innovative approach alongside the rapid maturation of quantum computing. Using the sample-based quantum diagonalization by IBM and RIKEN (featured on the cover of
Science Advances)
along with embedded wavefunction methods adapted by Cleveland Clinic to the question at hand, the team was able to report the first-known simulation of a
303-atom protein
achieved with quantum computers. Less than a year later, the team first scaled their method roughly 40 times while also achieving 210 times improvement in accuracy. In updated results recently published in September, the team advanced the work even further. Most notably, they were able to further improve the accuracy of their computations of the binding energies of the molecular system, which reflect how tightly the molecules are bound together and can predict how they could interact with other systems.
In addition, the team validated the workflow on a third supercomputer, JHPC-quantum GPU supercomputer “
ROQUO
,” RIKEN's newest system in a way that eliminated the need for complex manual operations and data transfers – pointing toward faster, more accessible research. By orchestrating CPUs, GPUs, and QPUs together, the team minimized the need for manual transfers and further reduced errors — an early demonstration of how classical and quantum computing can work in concert on complex scientific problems.
Taken together with the earlier results, these updates reflect continued progress on both the accuracy of computed binding energies and the time-to-solution enabled by the automated workflow.
The quantum-classical techniques developed by the team continues to reduce the computational overhead required to directly represent the chemistry of molecular systems with accuracy and is pushing the frontiers of what is possible with quantum-centric supercomputing in the field. The work has demonstrated a path to further increase the accuracy of how molecular system can be calculated and is a step towards helping researchers better predict how medicines may interact with protein targets.
The research team includes Kenneth Merz Jr, Akhil Shajan, Danil Kaliakin, Fangchun Liang of Cleveland Clinic, Yuichi Otsuka, Tomonori Shirakawa, Lukas Broers, Han Xu, Miwako Tsuji, Mitsuhisa Sato, Seiji Yunoki of RIKEN Center for Computational Science, and Ryo Wakizaka, Yukio Kawashima, Jun Doi, Hitomi Takahashi, Toshinari Itoko, Hiroshi Horii, Thaddeus Pellegrini, Javier Robledo Moreno, Kevin J. Sung, Ella Fejer, Robert Walkup, Seetharami Seelam, Mario Motta of IBM.
To read the full study, visit:
https://arxiv.org/abs/2605.01138
.
Research Support
This research is supported by NEDO (New Energy and Industrial Technology Development Organization), an organization under the jurisdiction of Japan's Ministry of Economy, Trade and Industry (METI)'s "Research and Development of Quantum-Supercomputers Hybrid Platform for Exploration of Uncharted Computable Capabilities" (Project Leader: Mitsuhisa Sato) as part of the "Project for Research and Development of Enhanced Infrastructures for Post 5G Information and Communications Systems (JPNP20017)."
About Cleveland Clinic
Cleveland Clinic
is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation, Cleveland Clinic has pioneered many
medical breakthroughs
, including coronary artery bypass surgery and the first face transplant in the United States. Cleveland Clinic is consistently recognized in the U.S. and throughout the world for its expertise and care. Among Cleveland Clinic’s 83,000 employees worldwide are more than 6,600 salaried physicians and researchers, and 21,900 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,725-bed health system that includes a 173-acre main campus near downtown Cleveland, 23 hospitals, 300 outpatient facilities, including locations in northeast Ohio; Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2025, there were 15.9 million outpatient encounters, 343,000 hospital admissions and observations, and 336,000 surgeries and procedures throughout Cleveland Clinic’s health system. Visit us at
clevelandclinic.org
. Follow us at
x.com/CleClinicNews
. News and resources are available at
newsroom.clevelandclinic.org.
About RIKEN
RIKEN is Japan’s leading national comprehensive research institute in the natural sciences, conducting research across a broad range of fields including physics, engineering, chemistry, mathematical and information sciences, computational science, biology, and medical science. The RIKEN Center for Computational Science (R-CCS) operates the world-class supercomputer Fugaku, providing computing resources to a wide range of users in universities, research institutions, and industry, and carries out research and development under the banner of “The Science of computing, by computing, and for computing”, contributing to the advancement of computational science and computer science.
For more information, visit
https://www.riken.jp/en/
.
About IBM
IBM is a leading global hybrid cloud and AI, and business services provider, helping clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM's legendary commitment to trust, transparency, responsibility, inclusivity and service.
For more information, visit
https://research.ibm.com
.
Media contacts:
Alicia Reale-Cooney
Cleveland Clinic
realeca@ccf.org
(216) 408-7444
R-CCS, Computational Science Promotion Division Outreach Group
r-ccs-koho@ml.riken.jp
Danielle Cerasani Estevez
IBM Research Communications
dcerasani@ibm.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。